{
  "id": 3608,
  "url": "https://nnemf.org/research/3608-a-randomized-trial-of-5-fluorouracil-leucovorin-cisplatin",
  "title": "A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas.",
  "authors": [
    "D Karacetin",
    "O Incekara"
  ],
  "journal": "Journal of B.U.ON. : official journal of the Balkan Union of Oncology",
  "year": "2004",
  "doi": null,
  "pmid": "17415824",
  "abstract": "PURPOSE: To compare the efficacy and toxicity between 2 regimens [5 fluorouracil (5-FU), leucovorin and etoposide (ELF) and 5-FU, leucovorin, cisplatin and epirubicin (PELF)] administered as postoperative adjuvant chemotherapy to patients with completely resected advanced gastric cancer. PATIENTS AND METHODS: Between 1998-2002, 78 patients with advanced gastric cancer were randomly assigned to receive 6 cycles of adjuvant ELF or PELF combination chemotherapy after complete surgical tumor resection. Endpoints were disease-free survival (DFS), overall survival and treatment toxicity. RESULTS: ELF was administered to 37 and PELF to 41 patients. Median overall survival was 12.3 months in the ELF group and 17.2 months in the PELF group (p=0.01), respectively. For the ELF group the median DFS was 17 weeks (range 7-160 weeks), while for the PELF group it was 35 weeks (range 12-172 weeks) (p=0.0004). Two-year overall survival was 8% (3 patients) in the ELF group and 24% (10 patients) in the PELF group (p=0.03). Grade 2 hematologic toxicity occurred in 21% (8 patients) in the ELF group and in 22% (9 patients) in the PELF group (p=0.5) and grade 3 in 29% (11 patients) in the ELF group and in 24% (10 patients) in the PELF group (p=0.2). Grade 2 non-hematologic toxicity was seen in 8% (3 patients) in the ELF group and in 17% (7 patients) in the PELF group (p=0.2). Grade 3 non-hematologic toxicity occurred in 29% (11 patients) in the ELF group and in 26.8% (11 patients in the PELF group) (p=0.2). CONCLUSION: PELF combination chemotherapy resulted in DFS and overall survival advantage compared with ELF. No significant differences in hematologic or non-hematologic toxicities between the two groups were registered. PELF is superior to ELF and represents a valid option for the treatment of gastric cancer.",
  "effect": "benefit",
  "evidence": "high",
  "extraction": {
    "studyType": "randomized_trial",
    "studyTypeLabel": "randomized trial",
    "effectDirection": "benefit",
    "evidenceLabel": "High",
    "population": "Patients with completely resected advanced gastric adenocarcinoma receiving postoperative adjuvant chemotherapy",
    "sampleSize": "78",
    "exposure": "ELF <1 MHz",
    "confidencePct": "74",
    "peerReviewed": "yes",
    "mainFindings": "In 78 randomized patients (ELF n=37; PELF n=41), median overall survival was 12.3 months with ELF vs 17.2 months with PELF (p=0.01). Median DFS was 17 weeks with ELF vs 35 weeks with PELF (p=0.0004), and 2-year overall survival was 8% vs 24% (p=0.03). No statistically significant differences in reported grade 2/3 hematologic or non-hematologic toxicities were observed between groups.",
    "outcomes": [
      "Disease-free survival (DFS)",
      "Overall survival",
      "Treatment toxicity (hematologic and non-hematologic",
      "grade 2 and grade 3)"
    ],
    "limitations": [],
    "keywords": [
      "gastric adenocarcinoma",
      "adjuvant chemotherapy",
      "randomized trial",
      "5-fluorouracil",
      "leucovorin",
      "cisplatin",
      "epirubicin",
      "etoposide",
      "overall survival",
      "disease-free survival",
      "toxicity"
    ],
    "hubs": [],
    "raw": "{\n  \"study_type\": \"randomized_trial\",\n  \"exposure\": {\n    \"band\": null,\n    \"source\": null,\n    \"frequency_mhz\": null,\n    \"sar_wkg\": null,\n    \"duration\": null\n  },\n  \"population\": \"Patients with completely resected advanced gastric adenocarcinoma receiving postoperative adjuvant chemotherapy\",\n  \"sample_size\": 78,\n  \"outcomes\": [\n    \"Disease-free survival (DFS)\",\n    \"Overall survival\",\n    \"Treatment toxicity (hematologic and non-hematologic; grade 2 and grade 3)\"\n  ],\n  \"main_findings\": \"In 78 randomized patients (ELF n=37; PELF n=41), median overall survival was 12.3 months with ELF vs 17.2 months with PELF (p=0.01). Median DFS was 17 weeks with ELF vs 35 weeks with PELF (p=0.0004), and 2-year overall survival was 8% vs 24% (p=0.03). No statistically significant differences in reported grade 2/3 hematologic or non-hematologic toxicities were observed between groups.\",\n  \"effect_direction\": \"benefit\",\n  \"limitations\": [],\n  \"evidence_strength\": \"high\",\n  \"confidence\": 0.74,\n  \"peer_reviewed_likely\": \"yes\",\n  \"keywords\": [\n    \"gastric adenocarcinoma\",\n    \"adjuvant chemotherapy\",\n    \"randomized trial\",\n    \"5-fluorouracil\",\n    \"leucovorin\",\n    \"cisplatin\",\n    \"epirubicin\",\n    \"etoposide\",\n    \"overall survival\",\n    \"disease-free survival\",\n    \"toxicity\"\n  ],\n  \"suggested_hubs\": []\n}"
  },
  "synthesis": null,
  "synthesisStatus": "pending",
  "originalHref": "https://pubmed.ncbi.nlm.nih.gov/17415824/",
  "sourceUrl": "https://rfsafe.org/mel/paper.php?id=3608",
  "updated": "2026-02-13 07:30:48"
}